Company Sponsored Sessions

* Subject to Change


Wednesday, October 3, 2018

13:00 – 14:30 Hall C4.4

PREVENTING HPV-RELATED DISEASE: FROM GLOBAL PERSPECTIVES TO LOCAL SOLUTIONS        

SESSION SUPPORTED BY: MSD

Symposium Organized by: Medscape LLC

13:00   Welcome and Introductions

K. A. Alexander, USA

13:05   The HPV Vaccine: What We Know

K. A. Alexander, USA

13:15   Spotlight on HPV-Related Cancer Prevention: Australia

S. Garland, Australia

13:35   Spotlight on HPV-Related Cancer Prevention: Malaysia

S. Kumarasamy, Malaysia

13:55   Spotlight on HPV-Related Cancer Prevention: Mongolia

B.Tsetsegsaikhan, Mongolia

14:15   Concluding Remarks

K. A. Alexander, USA

14:20   Audience Q & A

 

 

Thursday, October 4, 2018

07:45 – 09:15 Hall C4.9

CERVICAL CANCER DIAGNOSIS: SEEGENE'S HPV SCREENING OPENS A NEW ERA

SESSION SUPPORTED BY: SEEGENE

CHAIRS: S. Garland, Australia

07:45 The National Cervical Screening Program in Australia including Self-Collected Samples

D.Hawkes, Australia

08:15 Human Papillomavirus Genotyping in Cervical Cancer Screening: Data from the North Region of Portugal

H.Sousa, Portugal

08:45 A Study of HR-HPV Among Men who Have Sex with Men in DRC, AFRICA

L.Belec, France

 

Thursday, October 4, 2018

 

07:45 – 09:15 Hall C4.4

 

IMPLEMENTING POC CERVICAL CANCER SCREENING PROGRAMMES - MOVING TOWARDS SCALE UP        

 

SESSION SUPPORTED BY: CEPHEID

 

MODERATOR: A. Vallely, Australia

Health service delivery models for scaling use of point-of-care HPV test and treat strategies in high-burden, low-income settings

A. Vallely, Australia


Remote login software and other innovations to enhance scale-up of point-of-care HPV testing in high-burden, low-income settings

S. Badman, Australia


The feasibility and acceptability of self-sampling and HPV testing using the Cepheid Xpert HPV in a busy primary care facility     

Y.L. Woo, Malaysia

 

Preliminary Xpert HPV testing results from a large study of HIV-infected women living in Rwanda

G. Murenzi, Rwanda

 

Feasibility and acceptability of HPV Self collection and testing using Xpert HPV in Botswana

M. Kitheka, Botswana 

 

Q&A Discussion  

 

Thursday, October 4, 2018

13:30 – 15:00 Hall C4.4

THE UTILITY AND SIMPLICITY OF EXTENDED GENOTYPING: FROM THEORY TO PRACTICE

SESSION SUPPORTED BY: BD

CHAIR: J. Andrews, USA

The Latest Advances in Cervical Cancer Screening and Management: Performance and Genotyping Results from the BD Onclarity™ HPV Assay US Clinical Trial

T. C.  Wright, Jr., USA

The Impacts of Changing to Primary HPV Screening: for Women, Labs, Clinicians, Colposcopy, and Payers

R. Massey, New Zealand

Self-sampling and Extended Genotyping in a Primary HPV-based National Cervical Screening Program

D. Hawkes, Australia

 

Thursday, October 4, 2018

18:00 – 19:30  Hall C4.9

 

Meeting global challenges in cervical cancer screening through insight and proven clinical performance.

SESSION SUPPORTED BY: HOLOGIC, INC

18:00   Reception – Drinks and Hors D'oeuvres

18:15    Welcome and Introductions

Philipp Mueller, USA

18:20  Topic: Performance of the Aptima HPV assay in China

Prof. You-Lin Qiao, China

18:55  Topic: Aptima HPV performance in the CERVIVA trial: an interim update

Dr. Cara Martin, Ireland

19:20   Audience Q & A

 


Friday, October 5, 2018

13:00 – 14:30 Hall B1

EVOLUTION AND REVOLUTION IN CERVICAL CANCER SCREENING

SESSION SUPPORTED BY: ROCHE

MODERATOR: J. O'Leary, Ireland

The Transformation from Cytology to HPV Primary Screening: Best Practice and Lessons Learnt

A.Richards, Australia

One Country's Call for Change: The New Landscape of Cervical Cancer Screening in Ireland

J. O'Leary, Ireland

Expanding the Reach of Cervical Screening: cobas® HPV Testing and Self Sampling in Never-screened and Under-screened Women in Australia

D.Hawkes, Australia



Keep Me Updated